Discontinued drugs in 2007: Anti-infectives

Expert Opinion on Investigational Drugs

Volumn 18, Issue 1, 2009, Pages 1-11

  Ryder, Neil S ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Anti infectives; Discontinued drugs; HCV; Herpes virus; HIV; Vaccine

Indexed keywords

ACH 806; AG 702; AMPLIVAX; ANA 975; ANTISENSE OLIGONUCLEOTIDE; AVI 4065; BAVARIAN 1; BILN 1941; CAPRAVIRINE; GENIMM 4; HEPATITIS C VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; IR 103; ISATORIBINE; LAMIVUDINE; NCX 1000; NELFINAVIR; OLIGONUCLEOTIDE; PEGINTERFERON ALPHA; PLACEBO; PROTEINASE INHIBITOR; R 7025; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 520; ZIDOVUDINE;

CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION PREVENTION; INJECTION SITE REACTION; NAUSEA; NONHUMAN; PORTAL HYPERTENSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC VASCULITIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFECTIVE AGENTS; HUMANS; TIME FACTORS; TREATMENT FAILURE; VIRAL VACCINES;

EID: 67649344444     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802614920     Document Type: Review

References (14)

1. The Pharmaprojects database. Copyright © Informa UK Ltd
2. Sheldon J, Barreiro P, Vincent V. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin Invest Drugs 2007;16:1171-1181 (Pubitemid 47317010)
3. Fujiwara T, Sato A, el-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998;42:1340-1345
4. Sato A, Hammond J, Alexander TN, et al. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res 2006;70:66-74
5. Priddy FH, Brown D, Kublin J, et al. Merck V520-016 Study Group. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008;46:1769-1781
6. Timm A, Enzinger C, Felder E, et al. Genetic stability of recombinant MVA-BN. Vaccine 2006;24:4618-4621 (Pubitemid 43776775)
7. Yang W, Zhao Y, Fabrycki J, et al. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother 2008;52:2043-2052 (Pubitemid 351758541)
8. Fletcher S, Steffy K, Averett D. Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease. Curr Opin Investig Drugs 2006;7:702-708 (Pubitemid 44263174)
9. Fiorucci S, Antonelli E, Morelli O, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA 2001;98:8897-8902 (Pubitemid 32678124)
10. Koelle DM, Magaret A, McClurkan CL, et al. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. Clin Vaccine Immunol 2008;15:773-782 (Pubitemid 351967022)
11. Goodman M. Pharma industry performance metrics: 2007-2012E. Nat Rev Drug Discov 2008;7:795
12. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008;455:613-619
13. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008;128:133-147
14. Jensen DM, Ascione A. Future directions in therapy for chronic hepatitis C. Antivir Ther 2008;13(Suppl 1): 31-36 (Pubitemid 351542496)